We're now half way through the year. In another month we'll get a quarterly report for the just ended quarter. The question may be not what's happening financially, that will be reported, but will we get any guidance that goes beyond, we're still in a quiet period, you'll learn a great deal when we're not.
I certainly don't know what will be said, or as some suspect TLD will be issued before the quarterly. Anything is possible, and anything includes learning nothing more. In time we'll learn more, it's just impossible to say what that time will be, but I would be very surprised if it went beyond the SNO Abstracts due November 11th as I remember it.
I'm not saying we'll certainly present on DCVax-L alone at SNO, perhaps a Journal will proceed it, but if it fails to, I do think we'll make such a presentation. If we do have a Journal presentation prior to SNO, we'll have the info we want, but I still believe that Dr. Liau will present about much of what they're doing at UCLA, and she'll openly state that in virtually all the trials they're running one component in all of trials is DCVax-L. Yes, it's made at UCLA, but that's what they're making. I suspect that she'll summarize the results of the Phase 3 Trial, but her presentation will encompass all that's happening there. Of course I could be wrong, last year she cancelled presenting there, but this year I believe she'll know in advance, do I roll out the results of the Phase 3 Trial, or do I discuss all we're doing. I believe she'll have something to say there.
Gary
